TCRX TScan Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1783328 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-38.4%
TTM net income YoY19.3%
TTM EPS YoY20.5%
Revenue 3-yr CAGR-32.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,246.8%
Net margin-2,219.2%
FCF margin-2,153.3%
EBITDA margin-2,192.3%
Returns
ROE-126.4%
ROA-57.0%
ROIC (approx.)-3,777.3%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets73.1%
Debt / equity0.87x
Current ratio2.03x
Interest coverage-40.67x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue14.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $10.32M | $2.82M |
| R&D expense | $114.15M | $107.35M |
| SG&A expense | $31.99M | $30.29M |
| Operating income | -$135.81M | -$134.82M |
| Interest expense | $2.77M | $3.65M |
| Income tax | $0 | — |
| Net income | -$129.77M | -$127.50M |
| EBITDA | -$132.91M | -$130.72M |
| EPS (basic) | -1.00 | -1.14 |
| EPS (diluted) | -1.00 | -1.14 |
| Weighted avg. shares (diluted) | 129.78M | 111.99M |
| Balance sheet | ||
| Cash & equivalents | $152.41M | $183.72M |
| Short-term investments | — | $111.42M |
| Current assets | $157.21M | $292.72M |
| PP&E, net | $8.71M | $7.24M |
| Total assets | $228.79M | $371.12M |
| Current liabilities | $18.70M | $35.96M |
| Long-term debt | $32.53M | $32.07M |
| Total debt | $32.53M | $32.07M |
| Total liabilities | $105.67M | $130.15M |
| Shareholders' equity | $123.12M | $240.97M |
| Net debt | -$119.87M | -$151.65M |
| Cash flow statement | ||
| Operating cash flow | -$135.32M | -$110.82M |
| Capital expenditure | $4.41M | $3.83M |
| Free cash flow | -$139.73M | -$114.65M |
| Investing cash flow | $109.37M | -$52.61M |
| Financing cash flow | -$336,000 | $208.76M |
| Depreciation & amortization | $2.90M | $4.10M |
| Stock-based compensation | $11.71M | $9.55M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.